Clinical Trial Update: BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating BL-8040 with nelarabine for relapsed/refractory T-ALL and T-ALL/LBL was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Lymphoma
• T-acute Lymphoblastic Leukemia

Drugs mentioned

• BL-8040
• Nelarabine (Nelarabine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: T-Acute Lymphoblastic Leukemia, Adult T Lymphoblastic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-10-31